RE: Has Avacta missed the boat, globally now?29 Sep 2020 10:28
Abbott & Roche tests cannot be used without a medical professional. Certification for home(consumer) use is much more strict and takes much longer . Long term, I think, its the correct strategy. I think the reason Novacyt have their contract is to fill a gap, could be wrong but it kind of ties up with the time scales.
The long term value in AVACTA is the key thing here. They are not just a one trick pony and not only produce to sell, they also license. The AVA6000, if human trials go well, will be a show stopper.
Its a waiting game, and whilst frustrating, you have to have confidence in the company that you bought into....or play the short game and buy Novacyt shares. Nova's value will decrease considerably when something better is available..